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Abstract: BACKGROUND The metastatic potential of breast cancer cells has been strongly associated
with overexpression of the chemokine CXCL12 and the activity of its receptor CXCR4. Lidocaine, a
local anaesthetic that can be used during breast cancer excision, inhibits the growth, invasion, and
migration of cancer cells. We therefore investigated, in a breast cancer cell line, whether lidocaine can
modulate CXCL12-induced responses. METHODS Intracellular calcium, cytoskeleton remodelling, and
cell migration were assessed in vitro in MDA-MB-231 cells, a human breast cancer epithelial cell line,
after exposure to lidocaine (10 ￿M or 100 ￿M). RESULTS Lidocaine (10 or 100 ￿M) significantly inhibited
CXCR4 signalling, resulting in reduced calcium release (Fluo 340 nm/380 nm, 0.76 mean difference,
p<0.0001), impaired cytoskeleton remodelling (F-Actin fluorescence mean intensity, 21 mean difference,
P=0.002), and decreased motility of cancer cells, both in the scratch wound assay (wound area at 21
h, -19%, P<0.0001), and in chemotaxis experiments (fluorescence mean intensity, 0.16, P=0.0047). The
effect of lidocaine was not associated with modulation of the CD44 adhesion molecule. CONCLUSIONS
At clinical concentrations, lidocaine significantly inhibits CXCR4 signalling. The results presented shed
new insights on the molecular mechanisms governing the inhibitory effect of lidocaine on cell migration.
DOI: https://doi.org/10.1016/j.bja.2018.07.015
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Abstract
Background: The metastatic potential of breast cancer cells has been strongly associated with overexpression of the
chemokine CXCL12 and the activity of its receptor CXCR4. Lidocaine, a local anaesthetic that can be used during breast
cancer excision, inhibits the growth, invasion, andmigration of cancer cells. We therefore investigated, in a breast cancer
cell line, whether lidocaine can modulate CXCL12-induced responses.
Methods: Intracellular calcium, cytoskeleton remodelling, and cell migration were assessed in vitro in MDA-MB-231 cells,
a human breast cancer epithelial cell line, after exposure to lidocaine (10 mM or 100 mM).
Results: Lidocaine (10 or 100 mM) significantly inhibited CXCR4 signalling , resulting in reduced calcium release (Fluo 340
nm/380 nm, 0.76 mean difference, p<0.0001), impaired cytoskeleton remodelling (F-Actin fluorescence mean intensity, 21
mean difference, P¼0.002), and decreased motility of cancer cells, both in the scratch wound assay (wound area at 21 h,
19%, P<0.0001), and in chemotaxis experiments (fluorescence mean intensity, 0.16, P¼0.0047). The effect of lidocaine
was not associated with modulation of the CD44 adhesion molecule.
Conclusions: At clinical concentrations, lidocaine significantly inhibits CXCR4 signalling. The results presented shed new
insights on the molecular mechanisms governing the inhibitory effect of lidocaine on cell migration.
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Translational Studies
Editor’s key points
 Breast cancer metastasis involves chemokine signal-
ling that modulates cytoskeletal structure andmotility,
which might be sensitive to local anaesthetics.
 Lidocaine inhibited CXCR4 mediated migration of a hu-
man breast cancer cell line in vitro involving changes in
intracellular calcium release and the actin cytoskeleton.
 These findings provide a molecular mechanism for
possible beneficial effects of lidocaine in breast cancer
surgery through reduced tumour cell migration and
metastasis.
 Clinical studies are necessary to establish a clinical role
for lidocaine in reducing metastasis and improving
outcomes in cancer surgery.
Breast cancer is the most common diagnosed tumour and
represents the second leading cause of death in women.
Although chemotherapy, endocrine therapy, and radiotherapy
are effective, surgical removal of the tumour is still the best
option for a positive outcome.1 Retrospective and clinical
studies on patient cohorts undergoing cancer surgery suggest
that perioperative use of regional anaesthesia and local
anaesthetic agents might improve outcome.2 Recent in-
vestigations have shown that in lung carcinoma, local anaes-
thetics have anti-metastatic potential through inhibition of
cancer cell migration and of Src signalling.3
Themetastatic potential of breast cancer has been strongly
associated with overexpression of the chemokine CXCL12 and
the activity of its receptor CXCR4.4e7 Under homeostatic con-
ditions, the CXCL12/CXCR4 axis plays key roles in development
and immunity, while in cancer, it promotes tumour survival,
invasion, and metastasis.8,9 Chemokines have emerged as key
controllers of integrin function and cell locomotion.9 Chemo-
kine receptors aredifferentially expressedbyall leukocytesand
many non-haematopoietic cells, including cancer cells, and
constitute the largest branch of the g subfamily of rhodopsin-
like G protein-coupled receptors (GPCR), a receptor superfam-
ily that represents themost successful target of smallmolecule
inhibitors in modern pharmacology.10,11 As local anaesthetics
are known to modulate the activity of specific G-proteins,12,13
we investigated whether lidocaine at clinical concentrations
can modulate CXCR4 responses induced by CXCL12.
Methods
Cell line
MDA-MB-231 human breast cancer epithelial cells (CRM-HTB-
26TM from American Type Culture Collection, Rockville, MD,
USA), derived from pleural effusion, were cultured with Dulbec-
co’s Modified Eagle Medium (DMEM) containing D-glucose 4.5 g
L1, and glutaMAX (619650-026, GIBCO, ThermoFisher Scientific,
Switzerland) supplemented with fetal bovine serum 10% (16000-
044, GIBCO, ThermoFisher), and penicillin-streptomycin 1%
(15070063, GIBCO,ThermoFisherScientific). Cellswere incubated
under standard culture conditions (CO2 5%, O2 95%, 37C), and
experimentswereperformedwithcellsat70%e100%confluence.
Reagents
CXCL12 was chemically synthesised as described,14 and lido-
caine was from Sintetica® (Rapidocain 10 mg ml1, Mendrisio,
Switzerland).
Cell viability
MDA-MB-231 cells cultured in six-well plates were incubated
for 24 h with lidocaine (1 nM, 1, 10, 100 mM) or hydrogen
peroxide 2 mM (1-07209-0250, Merck, Kenilworth, NJ, USA),
used as positive control, for 3 h. Cells were stained with
Annexin V-fluorescein isothiocyanate (FITC) (556419, BD
PharmingenTM, San Jose, CA, USA) and propidium iodide 50 mg
ml1 (556463, BD PharmingenTM, San Jose, CA, USA) for 15 min
at room temperature and directly analysed by flow cytometry
(BD Canto, BD Biosciences, San Jose, CA, USA). Percentage of
viable, early/late apoptotic and necrotic cells was quantified by
FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Flow cytometric analysis
For detection of surface expression of CXCR4, CD44, and CD54 on
MDA-MB-231 cells, the following antibodies were used: CXCR4-
APC (555976, BD PharmingenTM), CD44-FITC (555478, BD Phar-
mingenTM),CD54-PE(322707,BioLegend,SanDiego,CA,USA).Cells
were incubated for 30 min at 4C following the manufacturer’s
instructions for each antibody. Samples were analysed by flow
cytometrywithBDCanto(BDBioscences)withtheFlowJosoftware
(Tree Star, Inc.). Relative mean fluorescence intensity was calcu-
lated as the ratio between stained and unstained samples.
Scratch wound assay
Migration of MDA-MB-231 cells stimulated by CXCL12 100 nM
was assessed in the presence or absence of lidocaine 10 mM or
100 mM. Cells were grown in six-well plates until confluence for
24 h. A scratch was created in each well using a small pipette
tip.15 For the experiments with the CD44 blocking antibody
(MA4400, Invitrogen, Waltham, MA, USA) used at 10 mg ml1,
cells were grown in 24-well plates until confluence. Stimula-
tion and scratch were performed as described above. Images
were recorded with a BD pathway 855 imager for 24 h main-
taining cells as described above, at 10 magnification. The
scratch wound area, expressed as percentage of the area at
time 0, was quantified using the open-source image analysis
software Fiji16 and normalised to time 0 for each condition.
Chemotaxis assays
Real-time cell migration of MDA-MB-231 cells was measured
using the m-Slide chemotaxis system from Ibidi (80326, Mar-
tinsried, Germany), according to the manufacturer’s in-
structions. Briefly, MDA-MB-231 cells were seeded at 4106
cells ml1 in chemotaxis medium [DMEM, fetal bovine serum
1%, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(Hepes) 20mM,pH7.4] in the central channel of the chemotaxis
slide, andwere cultured in standard conditions for 8 h to allow
adherence. Chemoattractant gradients were generated by
applying the following stimuli in the reservoirs of the chemo-
taxis slide: chemotaxismedium,CXCL12100nM, orCXCL12 100
nMwith lidocaine100mM.Phasecontrast imageswere recorded
for 18hwitha time lapseof 15minusing the ImageXpressMicro
4 Imager (Molecular Devices, San Jose, CA, USA) equipped with
an incubation systemset to CO2 5%,O2 95%, 37C, andwith a 4
objective. Single cell tracking was performed selecting the
centre ofmass in each frameusing themanual tracking plug-in
tool for the software ImageJ. Spider plots representing the tra-
jectories of tracked cells, forward migration indexes, accumu-
lated distance, and cell velocity were obtained using the
chemotaxis and migration plug-in tool from Ibidi.
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Actin polymerisation
Cells grown on poly-D-lysine-coated dishes (P35GC-0-14C,
MatTek Corporation, Ashland, MA, USA) were pre-treated with
lidocaine 10 mM or 100 mM for 24 h under culture conditions.
After washing with phosphate buffered saline, cells were
stimulated with complete medium in the presence or absence
of CXCL12 100 nM for 15 s, fixed in paraformaldehyde 4% in
phosphate buffered saline for 12 min on ice, and per-
meabilised with Triton-X-100 0.01% for 2 min on ice. Fila-
mentous actin was stained using phalloidin-FITC (4 mgml1, P-
5282, Sigma Aldrich, Saint Louis, MO, USA) for 30 min at room
temperature. Samples were analysed by confocal microscopy
(Leica SP5, Heerbrugg, Switzerland) at 63 magnification.
Mean fluorescence intensity was quantified using the open-
source image analysis software Fiji.16
Intracellular Ca2þ measurement
MDA-MB-231 cells (0.2106) were seeded on poly-D-lysine-
coated dishes (P35GC-0-14C, MatTek Corporation) and were
pre-treated with lidocaine 10 mM or 100 mM for 24 h under
culture conditions. To block the Gai subunit of CXCR4,
pertussis toxin from Bordetella pertussis (PTX) at 1 mg ml1
(P7208, Sigma Aldrich) was applied to the cells 2 h before Ca2þ
measurements. Cells were supplemented with FURA-2-
acetoxymethyl ester (Sigma Aldrich) 1 mM, incubated for 20
min at 37C, and washed with a buffer containing NaCl 136
mM, KCl 4.8 mM, HEPES 20 mM, and CaCl2 1 mM, pH 7.4. Im-
ages were recorded on an inverted microscope at 40 magni-
fication (Axiovert 200; Carl Zeiss, Oberkochen, Germany) with
excitation at 340 and 380 nm using the Polychrom V illumi-
nation system from TILL photonics GmbH (Gr€afelfing, Ger-
many). Chemokine was injected after 60 s, and recording
continued up to 150 s. The uncalibrated 340/380 ratio provides
a relative measure of cytoplasmic-free Ca2þ concentration.
Statistical analysis
Data are presented as mean (standard deviation). Normal
distribution was assessed using Shapiro-Wilk testing. Nor-
mally distributed data were analysed with Student’s t-test
(statistical significance between two groups), or two-way
analysis of variance followed by Dunnett’s multiple compari-
sons adjustment (statistical significance between more than
two groups).
Results
We first evaluated lidocaine toxicity on MDA-MB-231 cells.
Cellswere incubatedwith different concentrations of lidocaine
(1 nM, 1, 10, 100 mM) and induction of apoptosis or necrosis was
assessed after 24 h. Lidocaine did not induce apoptosis or ne-
crosis at any of the concentrations tested (Fig. 1).
Lidocaine effects on tumour cell migration
We then investigated whether lidocaine alters MDA-MB-231
chemokinesis or chemotaxis induced by CXCL12, the chemo-
kine agonist of the CXCR4 receptor. For this we used an in vitro
scratch wound assay, a technique widely applied for testing
in vitro cell migration of epithelial cancer cells,15 and an in vitro
chemotaxis assay that allows tracking directional cell migra-
tion in response to a chemotactic gradient. CXCL12 induced
significant MDA-MB-231 migration both in the scratch wound
assay (9 h, P¼0.0372; 12 h, P¼0.0003; 15, 18, 21 h, P<0.0001) and
chemotaxis assay (P¼0.0047), supporting the relevance of the
CXCL12/CXCR4 axis in tumour cell migration (Fig. 2). As shown
in Fig. 2A, lidocaine prevented closure of the scratch area
induced by CXCL12 at 10 mM or 100 mM (P<0.0001). Moreover,
lidocaine abrogated CXCL12 mediated chemotaxis as demon-
strated by a significant reduction in the forward migration
index (P¼0.0446), without altering cell velocity and cell accu-
mulated distance (Fig. 2B and C). These effects were not as a
result of changes in CXCR4 surface expression or alterations in
receptor trafficking as assessed by flow cytometry (data not
shown).
Different adhesion molecules expressed on epithelial cells
can play a role in cancer cell invasion and metastasis. There-
fore, the effect of lidocaine treatment was assessed on the
expression of CD44 and CD54 [intercellular adhesion molecule
1 (ICAM-1)] after stimulation with CXCL12. In comparison to
untreated cells, lidocaine pre-treatment induced an upregu-
lation of CD44 (P¼0.0226), which was observed also after
Fig 1. MDA-MB-231 cell viability after lidocaine treatment. (A)
Gating strategy to assess cell viability. One representative plot
obtained from cells treated with lidocaine 100 mM is shown. (B)
Percentage of viable, apoptotic and necrotic MDA-MB 231 cells
treated for 24 h with different lidocaine concentrations. Mean
(standard deviation) of three independent experiments. FITC,
fluorescein isothiocyanate.
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stimulation with CXCL12 (Fig. 3A, P¼0.0010), whereas no sig-
nificant differences were detected in CD54 expression (data
not shown). To understand whether lidocaine-mediated CD44
overexpression is essential for inhibition of MDA-MB-231
migration, the effect of CD44 blockade was tested in the
scratch wound assay. The CD44-neutralising antibody did not
restorecellmigration inCXCL12stimulatedcells in thepresence
of lidocaine (Fig. 3B), indicating that modulation of this adhe-
sion molecule is not essential for the observed effect, and sug-
gesting that lidocaine directly alters the response to CXCL12.
Lidocaine effects on cytoskeleton remodelling
Remodelling of the cytoskeleton, supported by actin poly-
merisation, is a crucial process for correct polarisation of cells
and motility during cell migration.17 CXCR4 triggering by
CXCL12 induces Ca2þmobilisation from intracellular stores as
a result of the activation of the Gai pathway.18 This is an
essential pathway for modulation of proteins with Ca2þ-
dependent activity that are involved in remodelling of the
cytoskeleton. CXCL12 triggering of CXCR4 resulted in an
intracellular Ca2þincrease, which could be blocked by the Gai
inhibitor pertussis toxin. Lidocaine pre-treatment partially
inhibited the Ca2þ mobilisation induced by CXCL12 (Fig. 4A).
We hypothesised that lidocaine inhibition of intracellular
Ca2þ increase impairs actin polymerisation, explaining the
observed reduction in cell migration. Therefore, a specific
staining for filamentous actin was performed in MDA-MB-231
cells pre-treated with lidocaine, and stimulated with CXCL12.
Exposure of untreated MDA-MB-231 cells to the chemokine
Fig 2. Lidocaine treatment inhibits CXCL12-induced in vitromigration of MDA-MB-231 cells. (A) Quantification of MDA-MB-231 cell motility,
expressed as percentage of the uncovered scratch wound area respective to time 0. Mean (standard deviation) of three independent ex-
periments of cells treated with lidocaine 10 mM (green) or 100 mM (red), in the presence or absence of CXCL12 100 nM. Statistical analysis
was by two-way analysis of variance (ANOVA). (B) Aggregated trajectories of individual cells in the presence of vehicle, CXCL12 100 nM, or
CXCL12 100 nM with lidocaine 100 mM. Red dots represent the position reached by each cell at the last time point recorded. A represen-
tative result, out of three independent experiments, is shown. (C) Quantification of MDA-MB-231 chemotaxis expressed as forward
migration index (FMI), accumulated distance, and cell velocity. Statistical analysis was by Student’s t-test. *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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resulted in rapid rearrangement of the cortical actin fibres,
with pronounced actin polymerisation (Fig. 4B). Lidocaine pre-
treatment at 10 and 100 mM inhibited cytoskeleton rearrange-
ment after CXCL12 stimulation (Fig. 4B), supporting the results
obtained in the migration assay. Quantification of mean fluo-
rescence intensity of phalloidin, which indicates levels of actin
polymerisation, confirmed the above data, showing a signifi-
cant decrease when cells pre-treated with lidocaine at 10 or
100 mM were stimulated with CXCL12 (Fig. 4C, P¼0.0011,
P¼0.0020, respectively). Of note, high lidocaine concentrations
(100 mM) also decreased basal actin polymerisation compared
with untreated cells (Fig. 4C, P¼0.0202).
Discussion
We show that lidocaine, at clinical concentrations, inhibits
CXCL12-induced CXCR4 signalling, which impairs the essen-
tial cascade of cytoskeleton remodelling, leading to a reduced
migration of breast cancer cells.
Epidemiological studies have suggested an association
between regional anaesthesia and a reduction in the inci-
dence of cancer recurrence.2 The underlying mechanism is
still unknown. One report suggested a possible systemic ef-
fect of reabsorbed local anaesthetic in preventing invasive-
ness of tumour cells released from the primary tumour
during surgery.19 This hypothesis has been supported by
in vitro studies, demonstrating that lidocaine affects motility
of a lung cancer cell line by reducing ICAM-1 and Src phos-
phorylation after tumour necrosis factor stimulation. The
reduced activity of ICAM-1 on tumour cells could inhibit
their adhesion to vascular endothelium, thus preventing
migration into tissues.3 And in a murine model of breast
cancer metastasis, lidocaine reduced pulmonary metastasis,
perhaps by anti-inflammatory or anti-angiogenic mecha-
nisms.20 Recent studies have shown that, in septic patients,
lidocaine can block neutrophil migration by inhibiting cell
arrest and transmigration through endothelial cells, affecting
G-protein signalling, without modulating expression of
adhesion molecules.21 The present study, focusing on breast
tumour cells, shows that lidocaine, at clinical concentra-
tions, can inhibit chemokine-induced cancer cell migration
by directly inhibiting the activity of CXCR4. These results
agree with studies performed on different cell types,3,21e23
showing that lidocaine affects the activity of the chemo-
kine class of GPCR, and providing new insights into the
molecular mechanisms governing its inhibitory effect on cell
migration.
Increasing evidence indicates that different classes of an-
aesthetics can exert either pro- or anti-metastatic effects,
which depend on cancer cell type, dosage, and administration
protocol.24 As an example, a potential pro-metastatic role of
volatile anaesthetics involving CXCR2 expression has been
described in ovarian cancer cells.25 Our data support further
studies to validate the role of lidocaine as an anti-metastatic
agent, and for reconsidering the perioperative treatment in
breast cancer. Indeed, perioperative continuous i.v. infusion of
lidocaine has been safely used to reduce systemic inflamma-
tion and bowel dysfunction after abdominal surgery.26
The chemokine system represents a fundamental commu-
nication bridge between cancer and stromal cells, essential in
maintaining and supporting tumour growth and metastasis.
The chemokine receptor CXCR4 and its ligand CXCL12, are
widely expressed in several types of tumours, and are both
targeted in cancer therapy.27 Numerous reports highlight the
crucial involvement of the CXCL12/CXCR4 chemokine axis
specifically in breast cancer cell metastasis to bone, lung, and
brain.4,28 In our work, lidocaine at clinical concentrations was
able to block CXCR4-mediated cell migration, acting on the
downstream signalling cascade. Lidocaine, by inhibiting
CXCL12-dependent Ca2þ release and actin polymerisation,
impaired the cytoskeleton remodelling required for directional
cell migration. Of note, high doses of lidocaine induced the loss
of cortical actin stress fibres, suggesting alteration of the basal
cellular cytoskeleton architecture.
Adhesion molecules, expressed on tumours, mediate the
interaction between cancer cells and the microenvironment,
Fig 3. Effect of lidocaine on CD44 expression, and relevance of CD44-induced adhesion on cell migration in lidocaine treated cells. (A)
Lidocaine induced CD44 up-regulation in the absence or presence of CXCL12. Relative mean fluorescence intensity (rMFI) is shown from
three independent experiments. Statistical analysis was with one-way analysis of variance (ANOVA). (B) CD44-mediated adhesion is not
required to inhibit CXCL12-induced migration in cells treated with lidocaine. Quantification of migration of MDA-MB-231 cells is expressed
in arbitrary units (AU). Covered area was normalised to respective time 0. Mean (standard deviation) of three independent experiments
pre-treating cells with lidocaine 100 mM in the presence or absence of a neutralising anti-CD44 antibody. *P<0.05, ***P<0.001.
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sustaining tumour progression and metastasis.29 We found
that in MDA-MB-231 cells, lidocaine treatment promotes
upregulation of CD44 expression, a transmembrane glyco-
protein important for cancer interaction with hyaluronic
acid, an essential component of the extracellular matrix.
Fuchs and colleagues30 pointed out a regulatory interplay
between CD44 and the CXCL12/CXCR4 axis, describing a
direct role of CD44 in the signalling of this chemokine
pathway. Our results show that the blockade of CD44 does
not restore CXCL12-mediated cell migration in MDA-MB-231
breast cancer cells, demonstrating that the lidocaine effect
is CD44-independent.
In conclusion, lidocaine can block a pathway involved in
cancer progression and metastasis, which opens the way for
further investigations of the activity of lidocaine on cells of the
immune system that might contribute to improved cancer
outcomes. Studies performed ex vivo on tumour and infil-
trating cells isolated after surgical removal from patients
treated with lidocaine and clinical trials are needed to confirm
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Fig 4. Effect of lidocaine treatment on intracellular Ca2þ increase and actin polymerisation after CXCL12 stimulation. (A) Changes of
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24 h. As a control, cells were pre-treated with pertussis toxin 1 mg ml1 for 2 h. Data are presented as ratio of fluorescence (Fluo 340 nm:380
nm) values over time. A representative result, out of three independent experiments, is shown. (B) CXCL12-mediated-actin polymerisation
measured by confocal microscopy using phalloidin coupled to fluorescein isothiocyanate (FITC). Cells, pre-incubated with lidocaine 10 mM
or 100 mM for 24 h, were stimulated with CXCL12 100 nM. Images of cell associated filamentous actin (green) were acquired for unsti-
mulated (left panels) or CXCL12-stimulated (right panels) cells. One representative experiment out of three is shown. (C) Quantification of
actin polymerisation was performed measuring mean fluorescence intensity (MFI) values of phalloidin for each experiment acquiring at
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analysis of variance (ANOVA). *P<0.05.
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